Skip to main content
Premium Trial:

Request an Annual Quote

New Dutch IVD Shop to Use Agilent Arrays in Breast-Cancer Project

NEW YORK, Aug. 21 (GenomeWeb News) - A new in vitro diagnostics company created by the authors of two important breast-cancer studies will use Agilent Technologies' microarray platform in its cancer research, the firms said today.


The company, Agendia, said it hopes to use the technology to develop the first microarray-based diagnostic to "predict the aggressiveness" of breast cancer tumors.


Because researchers are not allowed to use microarrays as diagnostic tools in the United States, Agendia, based in The Netherlands, said it will handle the microarray analysis of all tumor samples in its own country.

Agendia was founded by researchers from the Netherlands Cancer Institute, in Amsterdam, who co-authored a set of landmark breast-cancer studies reported last year in the New England Journal of Medicine and Nature. The Institute, together with Rosetta Inpharmatics, a wholly owned subsidiary of Merck, performed this research using Agilent arrays and tissue samples.

In those studies, researchers identified gene-expression patterns that "correlate to aggressive tumors" as well as to tumors less likely to spread, according to Agendia. Though preliminary, that research showed that gene-expression data "has the potential" to help physicians better target cancer therapeutic regimens.

Agendia said it plans to develop microarray-based tests for a host of diseases beside breast cancer.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.